Artificial intelligence chipmaker Cerebras Systems debuted its initial public offering at $185 per share. The stock soared to a high of $386.34 shortly after opening but closed the day at $311.07. After hours, Cerebras shares rose another 5% to nearly $330. “Mad Money” host Jim Cramer noted that “investors are taking a leap of faith” at this valuation, though he also described it as a “perfectly timed IPO,” which contributed to the significant initial jump.
SpaceX’s anticipated IPO filing faces scrutiny from major public funds over governance concerns, according to Leslie Picker. A source indicated that “The biggest challenge for the IPO right now is finding enough buyers to fill the book. Hard to do that when governance is blocking major would-be investors from seeking allocation.” New York State Comptroller Thomas DiNapoli issued a statement Thursday, asserting that SpaceX’s reported governance structure poses “significant risks to long-term investors.” He detailed these provisions, including “super voting shares for a select few, mandatory arbitration of shareholder claims, nearly insurmountable barriers to executive accountability, and limits on shareholder legal actions.” DiNapoli argued this structure would effectively leave shareholders without recourse regarding company operations, calling it “anathema to the transparency and legitimate board oversight required for a major publicly traded corporation.” He concluded that as SpaceX gains systemic importance in public markets, its governance “must at the bare minimum adhere to the baseline protections upon which long-term institutional capital depends.”
Cisco Systems reported strong earnings on Wednesday. Nvidia CEO Jensen Huang was reportedly in China with President Donald Trump, suggesting potential chip purchases from China. The overall excitement surrounding Cerebras also appeared to bolster the artificial intelligence sector. Cisco shares climbed 13.4% on Thursday, reaching a new high and achieving approximately a 40% gain over the past month. Nvidia also hit a new high, with its stock up around 20% in the last month.
Pharmaceutical firm Bristol Myers Squibb announced plans to collaborate more extensively with Chinese companies on drug development and testing. The company’s stock is currently down 10% from its March high.
Source link